The $400,000 SBIR Phase I award will support the further development of Tiba’s targeted delivery platform for a range of inflammatory lung diseases.
Tiba Biotech Announces Strategic Collaboration with CVIM to Advance RNA-Based Livestock Vaccines
April 9, 2026
Tiba announces strategic collaboration with Pirbright’s CVIM to accelerate the development of next-generation RNA vaccines targeting high-impact livestock diseases using the RNABL™ delivery platform.
Tiba Biotech Receives NCI Grant to Advance Next-Generation RNA Cancer Immunotherapies
September 25, 2025
The $400,000 SBIR Phase I award will support development of Tiba’s tissue-targeted delivery platform and proprietary enhanced self-amplifying RNA payloads.
NIH awards Tiba a Phase II SBIR grant to advance RNA vaccines against pandemic influenza
September 5, 2023
Tiba Biotech receives an NIH Phase II SBIR grant to continue its development of a multi-antigen RNA-based vaccine against the highly pathogenic H7N9 strain of influenza virus.
Tiba Biotech receives a Notice of Intent from NIAID to fund a Phase I SBIR to develop a novel RNA vaccine against a deadly tick bourn disease with the Cummings School for Veterinary Medicine
Tiba Biotech receives a Phase I SBIR grant from NIAID to develop a multi-antigen RNA-based vaccine against the highly pathogenic H7N9 strain of influenza virus.
A Shot in the Arm with 3D Printed Microneedle Patch
December 14, 2021
Tiba scientists are working with academic collaborators at the University of Pittsburg and Carnegie Mellon University to design a 3D printed micro-needle patch for intradermal mRNA vaccine delivery.
Today Tiba was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health. In response to an earlier Notice of Special Interest, this six-month grant is to develop an RNA-based multi-antigen vaccine for SARS-CoV-2.
Today Tiba was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health. In response to an earlier Notice of Special Interest, this six-month grant is to develop an RNA-based multi-antigen vaccine for SARS-CoV-2.
Today Tiba was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health. In response to an earlier Notice of Special Interest, this six-month grant is to develop an RNA-based multi-antigen vaccine for SARS-CoV-2.
© 2026 Tiba Biotech LLC. All rights reserved
Keep connected with us
Terms and Conditions
